A Texas judge ruled that HIV pre-exposure prophylaxis (PrEP) coverage under the Affordable Care Act is unconstitutional; an FDA advisory panel recommended the approval of an experimental drug for amyotrophic lateral sclerosis (ALS); Walmart and UnitedHealth Group are collaborating to provide preventive health care for older Americans.
US District Judge Reed O’Connor ruled Wednesday that required coverage of HIV pre-exposure prophylaxis (PrEP) under the Affordable Care Act (ACA) is unconstitutional and violates a Texas health care employer’s religious beliefs, the Associated Press reported. O’Connor also ruled that the US Preventive Services Task Force that recommends coverage violates the appointment clause of the US Constitution, but the ruling’s impact beyond the plaintiffs was not clearly defined. Soon after, The Hill reported the Biden administration’s announcement that it is reviewing the ruling, calling the ACA “the law of the land” for more than a decade. “That guarantee is critical to the health and wellbeing of millions of Americans, particularly LGBTQI+ Americans, people of color, pregnant women, and others,” Karine Jean-Pierre, White House press secretary, wrote in a Twitter thread. “The Administration is committed to protecting Americans’ access to free preventive health care and building upon the successes of the Affordable Care Act.”
Independent FDA advisers voted 7 to 2 Wednesday to recommend the approval of experimental amyotrophic lateral sclerosis (ALS) drug AMX0035, The Washington Post reported. The drug, which is considered safe and has gained support from patients with ALS and advocates, is manufactured by Amylyx. The FDA panel originally recommended against its approval in March 2022 due to insufficient efficacy data. However, additional data and and a vow by Amylyx to pull the drug if a larger study does not demonstrate its efficacy improved its case for FDA approval, and the panel also considered the severity and lack of treatments for ALS. The FDA is expected to decide whether to approve the drug by September 29.
Walmart and UnitedHealth Group are partnering to provide preventive health care for people 65 years and older, as well as virtual health care services for people of all ages, Reuters reported. The partnership will focus on value-based care and preventive care for common conditions among older adults, including heart disease and diabetes. In January 2023, services will initially be offered at 15 Walmart Health locations in Georgia and Florida. Walmart's health care personnel will use UnitedHealth’s Optum, which gives data analytics on patients to providers. Under the partnership, Walmart and UnitedHealth Group are also expected to launch a cobranded Medicare Advantage plan in Georgia.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More